These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8007683)

  • 1. Nephrectomy as a component of systemic treatment for renal cell carcinoma patients.
    Nastasi G; Porta C; Moroni M; Bobbio-Pallavicini E; Santagati G; Santagati C; Alessiani M
    J Surg Oncol; 1994 Jun; 56(2):81-2. PubMed ID: 8007683
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of nephrectomy in metastatic kidney cancer.
    Yonover PM; Sharma SK; Flanigan RC
    Cancer Treat Res; 2003; 116():119-35. PubMed ID: 14650829
    [No Abstract]   [Full Text] [Related]  

  • 3. Limitations of surgical curability in renal cell carcinoma.
    Geboers AD; Debruyne FM
    Prog Clin Biol Res; 1992; 378():175-86. PubMed ID: 1301579
    [No Abstract]   [Full Text] [Related]  

  • 4. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens.
    Wolf JS; Aronson FR; Small EJ; Carroll PR
    J Surg Oncol; 1994 Jan; 55(1):7-13. PubMed ID: 8289458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma--local recurrence/splenic injury.
    Sawczuk I
    J Urol; 1996 Jan; 155(1):37. PubMed ID: 7490889
    [No Abstract]   [Full Text] [Related]  

  • 6. [The medical treatment of renal cancer in adults].
    Sculier JP
    Rev Med Brux; 1989 May; 10(5):190-6. PubMed ID: 2662317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons in renal-cell carcinoma: status and prospects.
    De Mulder PH; Debruyne FM; Beniers AJ
    Prog Clin Biol Res; 1990; 348():49-59. PubMed ID: 1696737
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclic interferon gamma application in patients with renal cell carcinoma.
    Grups JW; Frohmüller HG
    Prog Clin Biol Res; 1990; 350():257-62. PubMed ID: 2117285
    [No Abstract]   [Full Text] [Related]  

  • 9. Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma.
    Novick AC
    Semin Oncol; 1995 Feb; 22(1):29-33. PubMed ID: 7855616
    [No Abstract]   [Full Text] [Related]  

  • 10. [Embolization for renal carcinoma].
    Li S; Dong Z; Li J
    Zhonghua Wai Ke Za Zhi; 1998 Feb; 36(2):101-2. PubMed ID: 11715549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of kidney occlusion on survival in renal cell carcinoma: a 10-year retrospective study].
    Latal D; Kautzky W; Wanek R; Kumpan W
    Z Urol Nephrol; 1990 Jan; 83(1):27-31. PubMed ID: 2330762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
    Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
    J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 14. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidative surgery after targeted therapy for renal cell carcinoma.
    Thomas AA; Campbell SC
    Urol Oncol; 2013 Aug; 31(6):914-9. PubMed ID: 22153755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of transvascular embolization in radical nephrectomy].
    Kurozumi T; Hamano K; Yagi H; Omoto T; Iwata Y
    Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1657-62. PubMed ID: 3251100
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: The evolving role of cytoreductive nephrectomy.
    Singla N; Hakimi AA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):505-506. PubMed ID: 31246591
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of cytoreductive nephrectomy in renal cell carcinoma.
    Chiong E; Wood CG; Margulis V
    Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.